Imbed Biosciences has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command’s (USAMRDC) Military Infectious Diseases Research Program (MIDRP), the company announced today.

According to a release, the money will accelerate the clinical development of an antibiofilm version of its next-generation Microlyte Matrix wound dressing that can kill bacteria hidden in biofilms.

“This award will fund a prospective human clinical trial of the novel antibiofilm matrix on donor site wounds in patients in need of autologous skin grafts,” Imbed Biosciences CEO Ankit Agarwal said in a statement. “We are honored to develop this advanced wound matrix for maximizing the readiness and performance of our warfighters in the field.”

The biotech company is at the forefront of the development of advanced wound care and surgical products, including those to support the armed services.